No Cover Image

Journal article 212 views 36 downloads

Intravenous sildenafil citrate and post-cardiac surgery acute kidney injury: a double-blind, randomised, placebo-controlled trial

Tracy Kumar, Hardeep Aujla, Marcin Woźniak, Will Dott, Nikol Sullo Orcid Logo, Lathishia Joel-David, Paolo Pais, Dawn Smallwood, Douglas Miller, Bryony Eagle-Hemming, Ana Suazo Di Paola, Shaun Barber, Cassandra Brookes, Nigel J. Brunskill, Gavin J. Murphy

British Journal of Anaesthesia, Volume: 124, Issue: 6, Pages: 693 - 701

Swansea University Author: Nikol Sullo Orcid Logo

  • 70509.VoR.pdf

    PDF | Version of Record

    © 2020 The Author(s). This is an open access article under the CC BY license.

    Download (620.55KB)

Check full text

DOI (Published version): 10.1016/j.bja.2020.01.030

Abstract

BackgroundThis study assessed whether i.v. sildenafil citrate prevented acute kidney injury in at-risk patients undergoing cardiac surgery with cardiopulmonary bypass.MethodsIn a double-blind RCT, adults at increased risk of acute kidney injury undergoing cardiac surgery in a single UK tertiary cent...

Full description

Published in: British Journal of Anaesthesia
ISSN: 0007-0912
Published: Elsevier BV 2020
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa70509
Abstract: BackgroundThis study assessed whether i.v. sildenafil citrate prevented acute kidney injury in at-risk patients undergoing cardiac surgery with cardiopulmonary bypass.MethodsIn a double-blind RCT, adults at increased risk of acute kidney injury undergoing cardiac surgery in a single UK tertiary centre were randomised to receive sildenafil citrate 12.5 mg kg−1 i.v. over 150 min or dextrose 5% at the commencement of surgery. The primary outcome was serum creatinine measured at six post-randomisation time points. The primary analysis used a linear mixed-effects model adjusted for the stratification variables, baseline estimated glomerular filtration rate, and surgical procedure. Secondary outcomes considered clinical events and potential disease mechanisms. Effect estimates were expressed as mean differences (MDs) or odds ratios with 95% confidence intervals.ResultsThe analysis population comprised eligible randomised patients that underwent valve surgery or combined coronary artery bypass graft and valve surgery, with cardiopulmonary bypass, between May 2015 and June 2018. There were 60 subjects in the sildenafil group and 69 in the placebo control group. The difference between groups in creatinine concentration was not statistically significant (MD: 0.88 μmol L−1 [–5.82, 7.59]). There was a statistically significant increase in multiple organ dysfunction scores in the sildenafil group (MD: 0.54 [0.02, 1.07]; P=0.044). Secondary outcomes, and biomarkers of kidney injury, endothelial function, and inflammatory cell activation, were not significantly different between the groups.ConclusionsThese results do not support the use of i.v. sildenafil citrate for kidney protection in adult cardiac surgery.
Keywords: acute kidney injury; cardiac surgery; cardiopulmonary bypass; phosphodiesterase type 5 inhibitors; renal protection; sildenafil citrate
College: Faculty of Medicine, Health and Life Sciences
Funders: British Heart Foundation (RG/13/6/29947), (CH/12/1/29419) to GJM, MW, TK, and HA; Leicester and Bristol National Institute for Health Research Cardiovascular Biomedical Research Units.
Issue: 6
Start Page: 693
End Page: 701

Similar Items